HIV an Illusion Toxic Shock

Total Page:16

File Type:pdf, Size:1020Kb

HIV an Illusion Toxic Shock SCIENTIFIC CORRESPONDENCE generated from a linear model could be a and Ho's] data is remarkable", note that vmons per day is not defined or function of both the baseline CD4 level Loveday et al. 8 report the use of a PCR­ addressed, nor can it be! No one else has and viral loads. Further studies with larg­ based assay and find only 200 HIV "virion access to either the unapproved drugs or er sample sizes are needed to resolve RNAs" per ml of serum of AIDS patients the branch PCR technology! What is the these discrepancies. - 1,000 times less than Ho and Wei. So benchmark rate for the turnover of CD4 Shenghan Lai, J. Bryan Page, Hong Lai much for the "remarkable concordance". cells in the general population? Departments of Medicine, Peter Duesberg To counter the 42 case studies of Wei et Psychiatry and Epidemiology, Department of Molecular and Cellular al. 1 and Ho et al.2, we at HEAL (Health University of Miami School of Medicine, Biology, University of California, Education AIDS Liason) can provide at Miami, Florida 33136, USA Berkeley, California 94720, USA least 42 people who are western-blot-posi­ Harvey Bialy tive for 'HIV', have low T4 cells, who are Bio/Technology, New York, not using orthodox procedures, and have HIV an illusion New York 10010, USA been healthy for years! On the other 1. Maddox, J. Nature 373, 189 (1995). hand, we can also provide you with hun­ SIR - In an editorial' in the 19 January 2. Ho, D.D. et al. Nature 373, 123-126 (1995). dreds of 'HIV+' people with high T4 cells, 3. Wei, X. et al. Nature 373, 117-122 (1995). issue of Nature, John Maddox invited 4. Duesberg, P. & Bialy, H. Genetica Suppl. (in the press). who were then hospitalized with oppor­ "Duesberg and his associates" to comment 5. Piatak, M. et al. Science 259, 1749-1754 (1993). tunistic diseases! Not to mention the 6. Wain-Hobson, S. Nature 373, 102 (1995). on the "HIV-1 dynamics" papers pub­ 7. Cao, Y. et al. New Engl. J. Med. 332, 201-208 (1995). thousands of AIDS cases without HIV lished the previous week, indicating that 8. Loveday, C. et al. Lancet 345, 820-824 (1995). which were conveniently renamed idio­ these new results should prove an embar­ • Peter Duesberg was offered space in pathic CD lymphocytopenia. rassment to us. Although we do not think Scientific Correspondence for 500 words of We at HEAL maintain that what is that a scientist should be embarrassed for his own choice, but declined. - Editor, called AIDS is no more complicated than pointing out inconsistencies and paradoxes Scientific Correspondence. a recreational drug-fear-medical drug in a hypothesis that have only been report­ disease syndrome which, with the excep­ edly resolved 10 years later, we none­ SIR - The most recent AIDS press tion of acute medical care, is out of the theless prepared a fully referenced, releases published as two "scientific arti­ purview of orthodox medicine. 1 2 approximately 2,000-word critique of the cles" in your magazine • indeed are the F. R. Buianouckas Ho et al. 2 and Wei et al. 3 papers that we most clever and, if possible, the most Department of Mathematics believed met the criteria of "not being deadly yet! Since March 1987, when Dues­ and Computer Science, longer than it needs to be, and pertaining berg first published his critique of retrovi­ Bronx Community College, to the papers at hand" that Maddox set rology3 and his proof that the "AIDS City University, Bronx, out in his widely read challenge. virus" is not sufficient to cause AIDS, the New York 104353, USA Unfortunately, he did not share our AIDS/HIV entrepreneurial gaggle have 1. Wei, X. et al. Nature 373, 117-122 (1995). view and agreed to publish only a radically railed against him both professionally and 2. Ho, D.D. et al. Nature 373, 123-126 (1995). shortened version, and only after he had financially. Rather than test Duesberg's 3. Duesberg, P.H. Cancer Res. 47, 1199-1220 (1987). personally "gone over it with a fine-tooth hypothesis or for that matter fund him to comb" to remove our perceived misrepre­ test his own hypothesis, you change your Toxic shock sentations of the issues. We found these model, which has not saved a single life, to new conditions so totally at variance with suit your own purposes, from HIV kills SIR - The recovery rate of CD4 + T cells the spirit of free and fair scientific debate CD4 cells directly, to HIV kills cells indi­ reported by Wei et al. 1 and Ho et al. 2 in that we could not agree to them. rectly, and now back to the latest direct HIV patients following therapy is remark­ 1 2 Readers of Nature who are interested in kill model of Wei et al. and Ho et al. • ably similar to that observed in another these questions, and feel that they do not Wei et al. 1 and Ho et al. 2 describe a acute clinical condition. We have docu­ need to be protected by Maddox from our viraemia that on administration of certain mented lymphocyte counts and propor­ ill-conceived logic, can find the complete drugs drops exponentially and raises CD4 tions of CD4 cells double-staining for text of our commentary in the monograph counts exponentially, seemingly without a CD45 isoforms in three patients during supplement to the most recent issue of trace of "mayhem". What is this viraemia episodes of toxic shock syndrome and one 4 Genetica • Here we would point out only of billions of RNA particles that can only following toxic shock-like syndrome. that the central claim of the Ho et al. 2 and be seen with an undocumented In these clinically defined conditions, Wei et al. 3 papers - that 105 HIV virions branch-PCR or PCR but not with a func­ bacterial superantigen initially induces per ml plasma can be detected in AIDS tional infectivity test? How do the authors massive T-cell and monocyte activation. patients with various nucleic-acid amplifi­ know that these RNA particles are infec­ There is subsequent apoptosis of the acti­ cation assays - is misleading. The senior tious and not defective? Is it reverse tran­ vated CD4 + cells, during which patients author of the Wei et al. paper has previous­ scriptase activity? Is it some protein that demonstrate a lymphopenia3, followed by ly claimed that the PCR method they used is unique to the quasispecies HIV? The the return to normality of the lymphocyte overestimates by at least 60,000 times tests for HIV are all flawed. What is this count as patients recuperate. The mean 5 the real titre of infectious HIV : free virus? How does one have free virus rate of change in the counts in the first 2 100,000/60,000 is 1.7 infectious HIVs per after immune response? Are not sympto­ weeks of recovery was 2.1, which com­ ml, hardly the "virological mayhem" allud­ matic people with AIDS HIV-positive, pares with 2.0 (ref. 1) and 1.8 (ref. 2). 6 ed to by Wain-Hobson • Further, Ho and a that is, don't they have antibodies against The similarity in rates of recovery sug­ different group of collaborators have just HIV? So what is free virus? gest that this rate has some value as a shown7 that more than 10,000 "plasma The Wei et al. and Ho et al. models do common measure of maximal CD4 T-cell virions", detected by the branched-DNA not account for other probable immune output to the circulation in adults. Slower amplification assay used in their Nature activity and the uniqueness of each indi­ rates may be observed, for instance, in paper, correspond to less than one (!) vidual. Haynes and Fauci showed in 1978 patients following radiotherapy or 4 infectious virus per ml. And infectious that hydrocortisone selectively caused chemotherapy • This rate decreases with units, after all, are the only clinically rele­ CD4 cells to hide in tissue. Indeed, what time; it took one patient 14 months to vant criteria for a viral pathogen. effect do multiple drugs have on CD4 reach a final CD4 + lymphocyte count of 9 3 Finally, in view ofWain-Hobson's state­ cells? The notion of clearance of one bil­ 1.4 x 10 cells cm- • The nature or mech­ ment6 that "the concordance of their [Wei lion CD4 cells per day versus one billion anisms of the brake on this rapid prolifer- NATURE · VOL 375 · 18 MAY 1995 197 .
Recommended publications
  • What You Should Know About HIV and AIDS
    WHAT YOU SHOULD KNOW ABOUT HIV & AIDS WHAT IS AIDS? AIDS is the Acquired Immune Deficiency Syndrome – a serious illness that makes the body unable to fight infection. A person with AIDS is susceptible to certain infections and cancers. When a person with AIDS cannot fight off infections, this person becomes ill. These infections can eventually kill a person with AIDS. WHAT CAUSES AIDS? The human immunodeficiency virus (HIV) causes AIDS. Early diagnosis of HIV infection is important! If you have been told that you have HIV, you should get prompt medical treatment. In many cases, early treatment can enhance a person’s ability to remain healthy as long as possible. Free or reduced cost anonymous and confidential testing with counseling is available at every local health department in Kentucky. After being infected with HIV, it takes between two weeks to three months before the test can detect antibodies to the virus. HOW IS THE HIV VIRUS SPREAD? Sexual contact (oral, anal, or vaginal intercourse) with an infected person when blood, pre-ejaculation fluid, semen, rectal fluids or cervical/vaginal secretions are exchanged. Sharing syringes, needles, cotton, cookers and other drug injecting equipment with someone who is infected. Receiving contaminated blood or blood products (very unlikely now because blood used in transfusions has been tested for HIV antibodies since March 1985). An infected mother passing HIV to her unborn child before or during childbirth, and through breast feeding. Receipt of transplant, tissue/organs, or artificial insemination from an infected donor. Needle stick or other sharps injury in a health care setting involving an infected person.
    [Show full text]
  • International Guidelines on HIV/AIDS and Human Rights 2006 Consolidated Version
    International Guidelines on HIV/AIDS and Human Rights 2006 Consolidated Version Second International Consultation on HIV/AIDS and Human Rights Geneva, 23-25 September 1996 Third International Consultation on HIV/AIDS and Human Rights Geneva, 25-26 July 2002 Organized jointly by the Office of the United Nations High Commissioner for Human Rights and the Joint United Nations Programme on HIV/AIDS OFFICE OF THE UNITED NATIONS HIGH COMMISSIONER FOR HUMAN RIGHTS Material contained in this publication may be freely quoted or reprinted, provided credit is given and a copy containing the reprinted material is sent to the Office of the United Nations High Commissioner for Human Rights, CH-1211 Geneva 10, and to UNAIDS, CH-1211 Geneva 27, Switzerland. The designations employed and the presentation of the material in this publication do not imply expression of any opinion whatsoever on the part of the Secretariat of the United Nations or UNAIDS concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. Published jointly by the Office of the United Nations High Commissioner for Human Rights and the Joint United Nations Programme on HIV/AIDS. HR/PUB/06/9 UN PUBLICATION Sales No. E.06.XIV.4 ISBN 92-1-154168-9 © Joint United Nations Programme on HIV/AIDS (UNAIDS) 2006. All rights reserved. Publications produced by UNAIDS can be obtained from the UNAIDS Information Centre. Requests for permission to translate UNAIDS publications—whether for sale or for noncommercial distribution—should also be addressed to the Information Centre at the address below, or by fax, at +41 22 791 4187, or e-mail: [email protected].
    [Show full text]
  • Discovery of Oncogenes: the Advent of Molecular Cancer Research
    COMMENTARY COMMENTARY Discovery of oncogenes: The advent of molecular cancer research Klaus Bister1 structural comparisons of the a and b subunits Institute of Biochemistry and Center for Molecular Biosciences, University of Innsbruck, of biologically cloned viruses, the transforming A-6020 Innsbruck, Austria principle was defined by the remarkably simple equation a − b = x and was later termed src td (for sarcoma). The first biochemical identifi- In their classic paper on the identification of defective ( ) mutant derivatives, they found cation of a cancer gene was achieved, initially the transforming principle of Rous sarcoma that all transforming virus stocks contained in a chicken virus. However, the principal proof virus (RSV) published 1970 in PNAS (1), two classes of RNA subunits, a larger one a b of a physical underpinning of the cancer gene Peter Duesberg at the University of California, ( ) and a smaller one ( ), whereas the non- hypothesis had tremendous impact on a fun- Berkeley, and Peter Vogt, then at the University transforming yet replication-competent mu- damental challenge of medicine, decoding the of Washington, Seattle, drew a seemingly sim- tants contained the smaller b subunits only. a molecular basis of human carcinogenesis. ple yet groundbreaking conclusion. When they Duesberg and Vogt concluded that the larger The genetic and biochemical investiga- analyzed the genomic RNAs of transforming, subunit contained the transforming princi- tions of the chicken tumor virus RSV and the acutely oncogenic RSV and of transformation- ple of RSV. Based on this and on subsequent persistent search for its transforming prin- ciple are a classic paradigm in cellular and molecular cancer research (2, 3).
    [Show full text]
  • CURRICULUM VITAE Updated on Jan 24, 2020
    T. Davtyan, Armenia CURRICULUM VITAE Updated on Jan 24, 2020 Surname Davtyan First name(s) Tigran Affiliation and official address Rhea Pharmaceutical Armenia LLC Armenia, 0084, Yerevan Gusan Sherami St., 2 Building (Malatia-Sebastia adm. district) Republic of Armenia Tel.: (+374-) 91 400994, 98-55-96-29 E-mail: [email protected] [email protected] Present Positions: Professor, Chief Scientist Rhea Pharmaceutical Armenia LLC Home address: Michurin str. 5, 23, 375041, Yerevan, Republic of Armenia. Tel: +374 10 55-96-29 Date and Place of birth: 1 December, 1966, Yerevan, Armenia Nationality: Armenian Citizenship: Republic of Armenia Passport ARM, AH0248176, 24 OCT 2006, 009 ID № 1112660259 Marital status: Married, has 2 children, 3 grandchild Education (degrees, dates, universities) 2016 Professor. Field: Biology 2003 Doctor of Biological Sciences (ScD). Field: Molecular Biology 1993 Candidate of Biological Sciences (Ph.D); Field :Genetics and Immunology 1989-1992 Ph.D. student, Laboratory of Genetic Mechanisms of Cell Malignization And Differentiation, Institute of Cytology, St. Petersburg, Russia. 1983-1988 Yerevan State Medical University, Faculty of Pharmacy Specialization (specify) Drug Design and quality control, HIV/AIDS and clinical immunology; Viral infections; immunity and stress resistance; Molecular mechanisms and Genetic regulation of innate immune response; Autoinflammation; 1 T. Davtyan, Armenia Career/Employment (employers, positions and dates) 2011- 2019 Director of Analytical Laboratory of Scientific Centre of Drug and Medical Thechnology Experttise JSC 1999 - 2011 Head of HIV-Clinical Trail Laboratory of the ARMENICUM Research Center, Yerevan, Rep. of Armenia. 1998 - 2006 Consultant on Science, Laboratory of Immunology, The Second Clinical Hospital of the Yerevan State Medical University, Rep.
    [Show full text]
  • A History of the Hiv/Aids Epidemic with Emphasis on Africa *
    UN/POP/MORT/2003/2 5 September 2003 ENGLISH ONLY WORKSHOP ON HIV/AIDS AND ADULT MORTALITY IN DEVELOPING COUNTRIES Population Division Department of Economic and Social Affairs United Nations Secretariat New York, 8-13 September 2003 A HISTORY OF THE HIV/AIDS EPIDEMIC WITH EMPHASIS ON AFRICA * UNAIDS and WHO ** * This document was reproduced without formal editing. ** UNAIDS, Geneva and WHO, Geneva. The views expressed in the paper do not imply the expression of any opinion on the part of the United Nations Secretariat. Quality and Coverage of HIV Sentinel Surveillance With a brief History of the HIV/AIDS Epidemic Workshop on HIV/AIDS and Adult Mortality in Developing Countries New York, 8-13 September 2003 2 1 History of the HIV/AIDS epidemic with emphasis on Africa In 1981, a new syndrome, the acquired immune deficiency syndrome (AIDS), was first recognized among homosexual men in the United States. By 1983, the etiological agent, the human immunodeficiency virus (HIV), had been identified. By the mid-1980’s, it became clear that the virus had spread, largely unnoticed, throughout most of the world. The HIV/AIDS pandemic consists of many separate epidemics. Each epidemic has its own distinct origin, in terms of geography and specific populations affected, and involve different types and frequencies of risk behaviors and practices, for example, unprotected sex with multiple partners or sharing drug injection equipment. Countries can be divided into three states: generalized, concentrated and low. Low Principle: Although HIV infection may have existed for many years, it has never spread to significant levels in any sub-population.
    [Show full text]
  • Duesberg and Critics Agree: Hemophilia Is the Best Test
    SPECIAL NEWS REPORT 1 REVIEWING THE DATA–I the Multicenter Hemophilia Cohort Study 66 2 (MHCS) sponsored by the National Cancer 65 3 Institute (NCI), follows 2000 hemophiliacs 64 4 Duesberg and Critics Agree: at 16 centers in the United States and West- 63 5 ern Europe. In 1989, the New England Journal 62 6 Hemophilia Is the Best Test of Medicine published a study from the 61 7 MHCS comparing 242 HIV-infected hemo- 60 8 philiacs who received high, medium, or low 59 9 Peter Duesberg and his critics in the com- addition, some researchers contacted by Sci- doses of factor VIII. If exposure to contami- 58 10 munity of AIDS researchers disagree vio- ence say Duesberg has drawn incorrect con- nants in factor VIII were the cause of the 57 11 lently about the cause of AIDS. But they clusions from their work. immune suppression seen in AIDS, it would 56 12 agree on one thing: Hemophiliacs provide a In making his argument that hemophili- be expected that those who received higher 55 13 good test of the hypothesis that HIV causes acs suffer from AIDS independent of HIV, doses of the factor would be more likely to 54 14 AIDS. Hemophiliacs offer a unique window Duesberg cites 16 studies showing that HIV- develop AIDS, says NCI’s James Goedert, 53 15 on the effects of HIV infection because there negative hemophiliacs have abnormal ratios the principal investigator of MHCS. But the 52 16 are solid data comparing those who have of two types of critical immune-system cells: study, says Goedert, found no association 51 17 tested positive for antibodies to HIV—and CD4 and CD8.
    [Show full text]
  • AIDS Denialism Beliefs Among People Living with HIV/AIDS
    J Behav Med (2010) 33:432–440 DOI 10.1007/s10865-010-9275-7 ‘‘There is no proof that HIV causes AIDS’’: AIDS denialism beliefs among people living with HIV/AIDS Seth C. Kalichman • Lisa Eaton • Chauncey Cherry Received: February 1, 2010 / Accepted: June 11, 2010 / Published online: June 23, 2010 Ó Springer Science+Business Media, LLC 2010 Abstract AIDS denialists offer false hope to people liv- example, claim that Nazi Germany did not systematically ing with HIV/AIDS by claiming that HIV is harmless and kill 6 million Jews (Shermer and Grobman 2000) and that AIDS can be cured with natural remedies. The current Global Warming Deniers believe that climatology is a study examined the prevalence of AIDS denialism beliefs flawed science with no proof of greenhouse gases changing and their association to health-related outcomes among the atmosphere (Lawler 2002). Among the most vocal people living with HIV/AIDS. Confidential surveys and anti-science denial movements is AIDS Denialism, an out- unannounced pill counts were collected from a conve- growth of the radical views of University of California nience sample of 266 men and 77 women living with HIV/ biologist Duesberg and his associates (1992, 1994; Duesberg AIDS that was predominantly middle-aged and African and Bialy 1995; Duesberg and Rasnick 1998). Duesberg American. One in five participants stated that there is no claims that HIV and all other retroviruses are harmless and proof that HIV causes AIDS and that HIV treatments do that AIDS is actually caused by illicit drug abuse, poverty, more harm than good. AIDS denialism beliefs were more and antiretroviral medications (Duesberg et al.
    [Show full text]
  • The Natural History of HIV-1 and HIV-2 Infections in Adults in Africa: a Literature Review Shabbar Jaffar,1, 2 Alison D
    The natural history of HIV-1 and HIV-2 infections in adults in Africa: a literature review Shabbar Jaffar,1, 2 Alison D. Grant,2 Jimmy Whitworth,2, 3 Peter G. Smith,1, 2 & Hilton Whittle4 Abstract About 30 million people in Africa are estimated to be living with human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS), yet data about the natural history of infection on the continent are sparse. We reviewed the literature on the natural history of HIV-1 and HIV-2 infections among African adults. Only one study, conducted in rural Uganda, has reported on survival from the time of HIV-1 seroconversion: the median was 9.8 years, which is similar to that reported in developed countries in the early stages of the epidemic and consistent with the findings from the follow-up of individuals identified by serological testing during community-based prevalence studies from Africa. Progression to symptomatic disease was faster in Uganda than in developed countries, due largely to the high background level of morbidity. Various studies suggest that people infected with HIV-2 survive longer and the course of the disease is possibly more variable than in people infected with HIV-1. However no studies have investigated survival from time of seroconversion among people infected with HIV-2. The majority of patients in hospital in Africa with either HIV-1 or HIV-2 have the clinical features of AIDS just before they die, and many are severely immunosuppressed. This is similar to the situation in developed countries before the introduction of highly active antiretroviral therapy (HAART).
    [Show full text]
  • Overview of HIV/AIDS Globally
    Natalia A. Feduschak, a Kaiser International Fellow and a freelance journalist, wrote and delivered the following lectures about HIV/AIDS to journalism students at the Kyiv National Taras Shevchenko University and Kyiv International University between April 2005 and November 2006. The lectures are based on her own research and interviews conducted in Ukraine and Europe, through resources provided by the Kaiser Family Foundation, Transatlantic Partners Against AIDS, numerous Ukrainian non-profit groups and the experiences of people living with HIV/AIDS. Lecture 1: Overview of HIV/AIDS Globally HIV/AIDS is one of the most important social, political and health issues affecting Ukraine today. Despite its importance, however, the subject remains far from society’s consciousness and is still not adequately covered in the Ukrainian media. The stories that do appear are often dry, consisting of statistics that mean little to the reader, or do not approach HIV/AIDS in a way that makes the issue pertinent to people’s lives. The purpose of this course is two-fold: to convince young journalists that HIV/AIDS merits consistent and in-depth reporting, and to give them the tools to do so. Over the next five weeks, we will look at the HIV/AIDS situation globally, regionally, and in Ukraine. In addition, we will discuss important related issues, such as HIV/AIDS as a national security issue, access to medication and the link between TB, alcoholism and HIV/AIDS. Finally, we will discuss source development and the ethics and professionalism of reporting on HIV/AIDS. Our reading materials will be varied, consisting of a handbook on reporting about HIV/AIDS, which was written by the Kaiser Family Foundation, a private U.S.
    [Show full text]
  • Guidelines for the Use of Antiretroviral Agents in Adults and Adolescent Living With
    Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV Developed by the DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents – A Working Group of the Office of AIDS Research Advisory Council (OARAC) How to Cite the Adult and Adolescent Guidelines: Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. Available at https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/ AdultandAdolescentGL.pdf. Accessed [insert date] [insert page number, table number, etc. if applicable] It is emphasized that concepts relevant to HIV management evolve rapidly. The Panel has a mechanism to update recommendations on a regular basis, and the most recent information is available on the HIVinfo Web site (http://hivinfo.nih.gov). What’s New in the Guidelines? August 16, 2021 Hepatitis C Virus/HIV Coinfection • Table 18 of this section has been updated to include recommendations regarding concomitant use of fostemsavir or long acting cabotegravir plus rilpivirine with different hepatitis C treatment regimens. June 3, 2021 What to Start • Since the release of the last guidelines, updated data from the Botswana Tsepamo study have shown that the prevalence of neural tube defects (NTD) associated with dolutegravir (DTG) use during conception is much lower than previously reported. Based on these new data, the Panel now recommends that a DTG-based regimen can be prescribed for most people with HIV who are of childbearing potential. Before initiating a DTG-based regimen, clinicians should discuss the risks and benefits of using DTG with persons of childbearing potential, to allow them to make an informed decision.
    [Show full text]
  • Lessons from an HIV Denialist in the Hills of Thailand
    Lessons from an HIV denialist in the hills of Thailand Brian Chang Alpert Medical School, Brown University, Providence, RI, USA I spent a month volunteering with Dr. Mark,* a physician in community. Further, denialist movements often go beyond science, the hill tribe villages of northern Thailand, in the summer of 2010. becoming “a social movement in which large numbers of people He was born in Myanmar, graduated from medical school in India come together and propound their views with missionary zeal.”3 and founded a small grassroots organization dedicated to the health HIV/AIDS denialism itself exists in a spectrum, ranging from of hill tribe villagers. He spent the last five years moving from village the rejection of the fact that HIV is a virus, to the denial of the caus- to village along the mountainous Thai-Burmese border, working on ative relationship between HIV and AIDS. I read arguments from sanitation projects and seeing patients in makeshift clinics. He is hard Dr. Peter Duesberg, a prominent cancer researcher, member of the working, humble and is known for his fluency in eight languages, in- National Academy of Sciences and a key voice in denying that HIV cluding all six of the local hill tribe dialects. During my month with causes AIDS. I also read claims from groups like RethinkingAIDS, Dr. Mark and his organization, I helped build toilets, collect water an international group of over 2,500 scientists, doctors and journal- supplies and run medical clinics. ists “reevaluating the HIV/AIDS hypothesis.”4-6 In fact, AIDS de- Through this experience and my discussions about HIV/AIDS nialists (including Dr.
    [Show full text]
  • HIV Subtype Diversity Worldwide
    REVIEW CURRENT OPINION HIV subtype diversity worldwide Nicholas Bbosaa, Pontiano Kaleebua,b, and Deogratius Ssemwangaa,b Purpose of review To provide a summary of the current data on the global HIV subtype diversity and distribution by region. HIV is one of the most genetically diverse pathogens due to its high-mutation and recombination rates, large population size and rapid replication rate. This rapid evolutionary process has resulted in several HIV subtypes that are heterogeneously globally distributed. Recent findings Subtype A remains the most prevalent strain in parts of East Africa, Russia and former Soviet Union countries; subtype B in Europe, Americas and Oceania; subtype C in Southern Africa and India; CRF01_AE in Asia and CRF02_AG in Western Africa. Recent studies based on near full-length genome sequencing highlighted the growing importance of recombinant variants and subtype C viruses. Summary The dynamic change in HIV subtype distribution presents future challenges for diagnosis, treatment and vaccine design and development. An increase in recombinant viruses suggests that coinfection and superinfection by divergent HIV strains has become more common necessitating continuous surveillance to keep track of the viral diversity. Cheaper near full-length genome sequencing approaches are critical in improving HIV subtype estimations. However, missing subtype data and low sequence sampling levels are still a challenge in some geographical regions. Video abstract http://links.lww.com/COHA/A14. Keywords diversity, HIV, subtype INTRODUCTION global HIV pandemic since its inception, other group As of 2017, there were 36.9 million people living with N, O and P viruses have not been disseminated widely. HIV worldwide with a majority of these infections in Group M viruses are further subdivided into nine sub-Saharan Africa [1].
    [Show full text]